Senior VP Business Development & Licensing
| IR contact (U.S.):|
Timothy McCarthy, CFA, MBA
Managing Director, Relationship Manager
LifeSci Advisors, LLC
As with so many things, covid-19 is having a major impact on research. At the point at which the pandemic struck, our Phase II vaccine trial was set up and awaiting the final local authorisations to begin. However, all clinical research not directly related to coronavirus has now been paused. This is because taking part in a trial would put patients at risk of catching covid-19, due to the travel involved as well as the inability to maintain social distancing during appointments. Similarly, all laboratory research not related to coronavirus is also on hold (due to the risk of spreading the virus with staff travelling to and from work) and King’s College London is closed. Hence work on our MAP test is currently paused too. We will be ready to go as soon as social distancing requirements are relaxed and permission is given for non-covid related clinical trials to restart and labs to re-open.
I would like to thank all our wonderful supporters for your continuing support during this very difficult time.
Posted on April 17, 2020 by admin1
Therapeutic Response in Crohn’s Disease through Downregulation of NF-κB Activation in the Absence of MAP Detection
We are delighted to share a new paper from Naser et al, showing that several antibiotics have demonstrated anti-inflammatory effects that are independent of their antibacterial properties. They show that anti-MAP triple antibiotics combination (RHB-104) exhibits anti-inflammatory and immunomodulatory activity alongside its known synergistic bactericidal activity against MAP infection. Very encouraging news! Thanks to Ahmad Qasem for sharing with us this latest piece of the MAP puzzle.
Click here to read the full paper.
Posted on November 19, 2020 by admin1
Crohn’s MAP Vaccine booster shot proven safe
At last, the paper we have been waiting for!
ABSTRACT: Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium avium subspecies paratuberculosis antigens as a single dose or as a booster vaccine following a simian adenovirus (ChAdOx2) prime. We demonstrate that a heterologous prime-boost schedule is well tolerated and induced T-cell immune responses.
Full paper from Gilbert et al here.
Posted on March 30, 2021 by admin1